SciBase is a pioneer in the field of dermatology, focusing on early detection and prevention through its unique point-of-care platform, Nevisense. Combining AI and advanced EIS technology, the company aims to elevate diagnostic accuracy and ensure proactive skin health management.
Founded in 1998 and headquartered in Sweden, SciBase has been at the forefront of dermatological advancements, with more than 20 years of research at the renowned Karolinska Institute.
Having been listed on the Nasdaq First North Growth Market since June 2, 2015, SciBase's commitment lies in minimizing patient suffering, enabling clinicians to improve and save lives, and ultimately reducing healthcare costs.
The company's last Venture Round investment took place on 28 March 2014, with Fouriertransform being the investing party. To learn more about SciBase, visit www.scibase.com.